IFNL3 and Cirrhosis: In subgroup analyses, there were no notable effects on Lambda/RBV versus alfa/RBV treatment differences with respect to gender, race (white or Asian), Hispanic/Latino ethnicity, HCV genotype, IL28B genotype, geographic region, or cirrhosis status (Fig. 2a).